Endogenous interleukin-1 alpha promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells

Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2927-34. doi: 10.1152/ajpheart.00700.2006. Epub 2007 Feb 9.

Abstract

During vascular disease and following injury, vascular smooth muscle cells (VSMC) proliferate and produce inflammation-promoting cytokines and chemokines. Similar phenotypic changes can be elicited in vitro by activation of Toll-like receptors (TLR) within VSMC. TLR-activated VSMC also produce IL-1 alpha, but it is unknown whether endogenous IL-1 alpha stimulates VSMC in an autocrine manner. Here we tested the hypothesis that endogenous IL-1 alpha contributes to TLR-induced proliferation and chemokine release in human VSMC by using RNA interference to knock down IL-1 alpha expression. Knockdown of IL-1 alpha abolished TLR-induced proliferation and suppressed TLR4-induced release of monocyte chemoattractant protein-1 (MCP-1) by VSMC, indicating that endogenous IL-1 alpha plays a crucial role in both responses. Serum, PDGF, FGF-2, and EGF each increased cellular IL-1 alpha concentrations, and IL-1 alpha knockdown inhibited serum- and PDGF-induced DNA synthesis, further indicating that endogenous IL-1 alpha also contributed to VSMC responses to growth factors. IL-1 receptor antagonist, a competitive inhibitor of IL-1 receptor I (IL-1RI), also attenuated TLR-induced proliferation and both basal and TLR-induced MCP-1 expression, indicating at least a partial role of the IL-1RI in mediating these responses. The results support the hypothesis that autocrine actions of endogenous IL-1 alpha, mediated at least in part via IL-1RI signaling, contribute to a proproliferative and proinflammatory phenotypic shift in TLR-activated human VSMC, which might play a pathogenic role in vascular disorders.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Autocrine Communication*
  • Cell Proliferation*
  • Cells, Cultured
  • Chemokine CCL2 / metabolism
  • Coronary Vessels / metabolism
  • Coronary Vessels / pathology
  • Coronary Vessels / physiopathology
  • Epidermal Growth Factor / metabolism
  • Fibroblast Growth Factor 2 / metabolism
  • Humans
  • Inflammation / metabolism*
  • Inflammation / pathology
  • Inflammation / physiopathology
  • Interleukin 1 Receptor Antagonist Protein / metabolism
  • Interleukin-1alpha / genetics
  • Interleukin-1alpha / metabolism*
  • Muscle, Smooth, Vascular / metabolism*
  • Muscle, Smooth, Vascular / pathology
  • Muscle, Smooth, Vascular / physiopathology
  • Myocytes, Smooth Muscle / metabolism*
  • Myocytes, Smooth Muscle / pathology
  • Phenotype
  • Platelet-Derived Growth Factor / metabolism
  • RNA Interference
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Receptors, Interleukin-1 Type I / metabolism*
  • Serum / metabolism
  • Toll-Like Receptor 3 / metabolism
  • Toll-Like Receptor 4 / metabolism
  • Toll-Like Receptors / metabolism*
  • Transfection

Substances

  • CCL2 protein, human
  • Chemokine CCL2
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1alpha
  • Platelet-Derived Growth Factor
  • RNA, Small Interfering
  • Receptors, Interleukin-1 Type I
  • TLR3 protein, human
  • TLR4 protein, human
  • Toll-Like Receptor 3
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • Fibroblast Growth Factor 2
  • Epidermal Growth Factor